UNSPSC 51262413: Reproterol hydrochloride

This classification denotes a metaproterenol analog C18H23N5O5.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y4I1COJ8W8, chemically known as 1h-purine-2,6-dione, 7-(3-((2-(3,5-dihydroxyphenyl)-2-hydroxyethyl)amino)propyl)-3,7-dihydro-1,3-dimethyl-, monohydrochloride, but more generally known as reproterol hydrochloride, which bears US NIH Compound Identifier 3032600. European Medicines Agency schedules Reproterol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04218MIG.

Most nations, for tariff and trade purposes, schedule reproterol hydrochloride under HS 29395900 and SITC 54145. As of Q4 2014, REPROTEROL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN1C2C(C(=O)N(C1=O)C)N(CN2)CCCNCC(C3CC(CC(C3)O)O)O.CL.

UNSPSC 51262413 Reproterol hydrochloride is a Commodity code that represents a specific pharmaceutical product — a bronchodilator medication used in respiratory treatment. However, recent state and local procurement activity tagged under this code shows little direct relevance to reproterol itself. Instead, the tagged opportunities involve naloxone procurement and pharmacy benefit program management, neither of which aligns with the code's nominal scope. The mismatch suggests either tagging error in the source records or a downstream categorization issue in the state and local procurement platforms that indexed these opportunities.

The sole concrete opportunity with a clear issuing body and solicitation timeline is Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026, for naloxone and drug deactivation systems — a public health supply contract for 1,900 units of naloxone and 800 deactivation systems annually, with quarterly deliveries and a two-year initial term plus one-year renewal option. The second record, a Texas Health and Human Services Commission RFI posted April 3, 2026, is an exploratory information-gathering exercise about direct-to-manufacturer prescription programs and does not constitute an active procurement opportunity. No state and local opportunities in the source directly solicit reproterol hydrochloride or other products within the code's pharmaceutical scope. Firms evaluating this code for state and local procurement activity should verify tagging accuracy in their research systems, as the indexed opportunities do not reflect genuine market demand under this commodity classification.